ArticleTissue engineering. Part A2014
Low-oxygen culture conditions extend the multipotent properties of human retinal progenitor cells.
Article in Tissue engineering. Part A, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 49 citations in OpenAlex.
- Direct Chemical Reprogramming of Human Fibroblasts into Retinal Progenitor-like Cells for Ocular Delivery.Journal of functional biomaterials · 2026Article
- Establishment of human embryonic stem cell line expressing EGFP reporter driven by human RAX promoter for evaluation of retinal progenitor cell potency.In vitro cellular & developmental biology. Animal · 2026Article
- Retinal cytoarchitecture is preserved in an organotypic perfused human and porcine eye model.Acta neuropathologica communications · 2024Article
- Retinitis pigmentosa and stem cell therapy.International journal of ophthalmology · 2024Review
- Exosome-mediated inhibition of microRNA-449a promotes the amplification of mouse retinal progenitor cells and enhances their transplantation in retinal degeneration mouse models.Molecular therapy. Nucleic acids · 2023Article
- [Effects of leptin on proliferation and differentiation of hypoxic rat retinal progenitor cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Update of application of olfactory ensheathing cells and stem cells/exosomes in the treatment of retinal disorders.Stem cell research & therapy · 2022Review
- Retina stem cells, hopes and obstacles.World journal of stem cells · 2021Review
- Insight into Hypoxia Stemness Control.Cells · 2021Review
- Construction and characterization of EGFP reporter plasmid harboring putative human RAX promoter for in vitro monitoring of retinal progenitor cells identity.BMC molecular and cell biology · 2021Article
- Maturation and Protection Effect of Retinal Tissue-Derived Bioink for 3D Cell Printing Technology.Pharmaceutics · 2021Article
- Intravitreal Injection of Human Retinal Progenitor Cells for Treatment of Retinal Degeneration.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Retinal stem cell transplantation: Balancing safety and potential.Progress in retinal and eye research · 2020Review
- Low-oxygen and knock-out serum maintain stemness in human retinal progenitor cells.Molecular biology reports · 2020Article
- In Situ Cross-linking Hydrogel as a Vehicle for Retinal Progenitor Cell Transplantation.Cell transplantation · 2019Article
- Organoid-derived C-KitNature communications · 2019Article
- Regenerating Eye Tissues to Preserve and Restore Vision.Cell stem cell · 2018Review
- Compound anisodine affects the proliferation and calcium overload of hypoxia-induced rat retinal progenitor cells and brain neural stem cells via the p-ERK1/2/HIF-1α/VEGF pathway.Experimental and therapeutic medicine · 2017Article
- A Novel Neuroprotective Small Molecule for Glial Cell Derived Neurotrophic Factor Induction and Photoreceptor Rescue.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2017Article
- Progress of stem/progenitor cell-based therapy for retinal degeneration.Journal of translational medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposeDevelopment of an effective cell-based therapy is highly dependent upon having a reproducible cell source suitable for transplantation. One potential source, isolated from the developing fetal neural retina, is the human retinal progenitor cell (hRPC). One limiting factor for the use of hRPCs is their in vitro expansion limit. As such, the aim of this study was to determine whether culturing hRPCs under 3% O2 would support their proliferative capacity while maintaining multipotency.
methodsTo determine the effect of low oxygen on the ability of hRPCs to self-renew, rates of proliferation and apoptosis, telomerase activity, and expression of proliferative, stemness, and differentiation markers were assessed for hRPCs cultured in 3% and 20% oxygen conditions.
resultsCulture under 3% oxygen increases the proliferation rate and shifts the proliferation limit of hRPCs to greater 40 divisions. This increased capacity for proliferation is correlated with an upregulation of Ki67, CyclinD1, and telomerase activity and a decrease in p53 expression and apoptosis. Increased expression of cMyc, Klf4, Oct4, and Sox2 in 3% O₂ is correlated with stabilization of both HIF1α and HIF2α. The eye field development markers Pax6, Sox2, and Otx2 are present in hRPCs up to passage 16 in 3% O₂ . Following in vitro differentiation hRPCs expanded in the 3% O₂ were able to generate specialized retinal cells, including rods and cones.
conclusionsLow-oxygen culture conditions act to maintain both multipotency and self-renewal properties of hRPCs in vitro. The extended expansion limits permit the development of a clinical-grade reagent for transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.